Timeframe: 2021 – 2022 Goal: Model development Principal Investigator: Mark Yarchoan, MD, Associate Professor, Oncology/Division of GI Malignancies, Sidney Kimmel Comprehensive Cancer Center Efforts to identify novel therapies for FLC have been confounded by a lack of preclinical models that accurately reflect the genetics and biology of the disease. This study aims to establish and …
Timeframe: 2022 – 2024 Goal: Advance immunotherapy for FLC, by defining the most promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigators: Praveen Sethupathy, PhD, Biomedical Sciences, Cornell University; Mark Yarchoan, MD, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Paul G. Thomas, PhD, Immunology, St. Jude Children’s Research Hospital …
Timeframe: 2020 – 2022 Goal: Assess potential to induce immune response with a FLC therapeutic vaccine Principal Investigator: Mark Yarchoan, MD, Associate Professor, Oncology/Division of GI Malignancies, Sidney Kimmel Comprehensive Cancer Center This clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns …
Timeframe: 2019-2022 Goal: Assess potential to induce immune response with a FLC therapeutic vaccine Principal Investigator: Mark Yarchoan, MD, Associate Professor, Oncology/Division of GI Malignancies, Sidney Kimmel Comprehensive Cancer Center FLC is a rare and often lethal form of liver cancer for which there is no standard treatment option beyond surgery. Immune checkpoint inhibitors are …
Timeframe: 2016 – 2019 Goal: Define the dominant immune checkpoint pathway in FLC Principal investigator: Amy K. Kim, M.D., Assistant Professor Tumor cells produce immune checkpoint molecules that suppress host immune response and allow evasion from immune responses. The discovery of drugs that block these immune checkpoints have revolutionized current cancer treatment. Anti-PD1 (programmed cell …
Timeframe: 2010 Goal: Identify biomarkers Principal Investigator: Michael Torbenson, MD, Department of Pathology, Johns Hopkins University (Currently at Mayo Clinic) Early identification of tumors is essential for aggressive treatment. The majority of fibrolamellar carcinoma (FLC) patients have metastatic disease at the time of diagnosis. Therefore, identification of biomarkers for FLC is essential. Using a broad …